This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ribeiro, F. R. Articles by Teixeira, M. R. Search for Related Content PubMed PubMed Citation Articles by Ribeiro, F. R. Articles by Teixeira, M. R.

8q Gain Is an Independent Predictor of Poor Survival in Diagnostic Needle Biopsies from Prostate Cancer Suspects

Authors' Affiliations: Departments of ¹ Genetics, ² Pathology, ³ Radiology, and ⁴ Urology, Portuguese Oncology Institute-Porto; ⁵ Fernando Pessoa University; ⁶ Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences, University of Porto, Porto, Portugal; ⁷ Department of Genetics, Institute for Cancer Research, Norwegian Radium Hospital; and ⁸ Department of Molecular Biosciences, University of Oslo, Oslo, Norway

Requests for reprints: Manuel R. Teixeira, Department of Genetics, Portuguese Oncology Institute, Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal. Phone: 351-225084000; Fax: 351-225084016; E-mail: mteixeir{at}ipoporto.min-saude.pt.

Purpose: The main procedure to confirm a suspected diagnosis of prostate cancer is histologic analysis of ultrasound-guided sextant prostate biopsies. As it is difficult to reliably assess tumor stage and grade in such minute samples, the clinical significance of some tumor foci remains unclear. Genetic markers that could augment pretreatment prognostic information would improve the clinical management of the disease.

Experimental Design: We have analyzed by comparative genomic hybridization a consecutive series of prostate needle biopsies obtained prospectively from 100 prostate cancer suspects. For 25 of these patients, a second independent biopsy core was analyzed to assess possible tumor heterogeneity. Additionally, a three-color fluorescent in situ hybridization assay was done in paraffin-embedded biopsy cores to validate the comparative genomic hybridization findings and to confirm their prognostic value.

Results: Sixty-one of 100 biopsy samples had morphologic evidence of prostate cancer and 41 (67%) of these displayed genomic copy number changes as opposed to none of the morphologically normal biopsies. The presence of losses, amplifications, and the total number of genomic imbalances were significantly associated with poorly differentiated tumors. Kaplan-Meier curves with log-rank test showed that patients whose tumors displayed 8q gains had a significantly worse survival even when tumor grade was taken into account (P = 0.008). Restricting the analysis to cases with Gleason score 7, the most troublesome category in terms of prognostic information, gains at 8q were still significantly associated with poor survival (P = 0.011), something that was confirmed by fluorescent in situ hybridization in an independent series of biopsies with much longer follow-up time (P = 0.023).

Conclusions: We show that whole genomic information can be obtained from minute needle biopsies of prostate cancer suspects and that genetic data can provide additional prognostic information before a therapeutic decision is taken.

This article has been cited by other articles:

				D. Wokolorczyk, B. Gliniewicz, A. Sikorski, E. Zlowocka, B. Masojc, T. Debniak, J. Matyjasik, M. Mierzejewski, K. Medrek, D. Oszutowska, et al. A Range of Cancers Is Associated with the rs6983267 Marker on Chromosome 8 Cancer Res., December 1, 2008; 68(23): 9982 - 9986. [Abstract] [Full Text] [PDF]

				D. Lin, A. Watahiki, J. Bayani, F. Zhang, L. Liu, V. Ling, M. D. Sadar, J. English, L. Fazli, A. So, et al. ASAP1, a Gene at 8q24, Is Associated with Prostate Cancer Metastasis Cancer Res., June 1, 2008; 68(11): 4352 - 4359. [Abstract] [Full Text] [PDF]

				F. Kosari, J. M. A. Munz, C. D. Savci-Heijink, C. Spiro, E. W. Klee, D. M. Kube, L. Tillmans, J. Slezak, R. J. Karnes, J. C. Cheville, et al. Identification of Prognostic Biomarkers for Prostate Cancer Clin. Cancer Res., March 15, 2008; 14(6): 1734 - 1743. [Abstract] [Full Text] [PDF]

				R. Henrique, F. R. Ribeiro, D. Fonseca, M. O. Hoque, A. L. Carvalho, V. L. Costa, M. Pinto, J. Oliveira, M. R. Teixeira, D. Sidransky, et al. High Promoter Methylation Levels of APC Predict Poor Prognosis in Sextant Biopsies from Prostate Cancer Patients Clin. Cancer Res., October 15, 2007; 13(20): 6122 - 6129. [Abstract] [Full Text] [PDF]

				E. A. Platz Genetic Variation at 8q24 as a Susceptibility Factor for Prostate Cancer: Definitive Results from Epidemiologic Studies? Cancer Res., April 1, 2007; 67(7): 2905 - 2907. [Full Text] [PDF]